RBC Capital lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $1 from $3 and keeps a Sector Perform rating on the shares. The company’s Phase III study of oral ganaxolone in tuberous sclerosis complex rare epilepsy did not meet the primary endpoint of significant difference in placebo-adjusted percent change, though while ganaxolone’s journey under the company may be coming to an end, its revenue stream in CDD may still have “leverageability”, and if the stock remains depressed after yesterday’s 80% downside move, there could potentially be an arbitrage opportunity, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals price target lowered to $4 from $13 at Cantor Fitzgerald
- Marinus Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
- Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen
- Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies
- Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue